As of November 16, 2026, no final FDA decision exists: on April 30, 2026 FDA proposed to leave semaglutide and tirzepatide off the 503B bulks list for outsourcing facilities, and that list does not govern state-licensed 503A pharmacies.
No insurance needed. Two programs to check.
Eden$99 a monthWeight loss warranty includedCheck price →
Collective$59 a month, drug priceLowest price on our chartCheck price →
The record
| Docket | FDA-2018-N-3240 |
|---|---|
| Proposal | List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act, document 2026-08552 (91 FR 23431) |
| FDA announced it | April 30, 2026 |
| Published in the Federal Register | May 1, 2026 |
| Comment deadline | July 30, 2026, moved from June 30, 2026 (document 2026-12937) |
| Final decision | None published as of November 16, 2026 |
What FDA proposed
On April 30, 2026 FDA said it proposes to leave semaglutide, tirzepatide and liraglutide off the 503B bulks list. It found no clinical need for outsourcing facilities to compound them from bulk drug substances. The notice ran in the Federal Register on May 1, 2026 as document 2026-08552, docket FDA-2018-N-3240.
The notice says FDA does not count a lower price than the FDA-approved drug, or a more convenient form, as a clinical need.
Comments were due June 30, 2026. FDA moved that to July 30, 2026, and the comment period is now closed.
Where it stands on November 16, 2026
The proposal is not final. The notice calls itself preliminary and says it does not reflect a final Agency decision. On November 16, 2026 the Federal Register held no later document on docket FDA-2018-N-3240 than the extension of June 26, 2026.
FDA's own 503B list page, last updated August 21, 2023, lists final decisions only. Semaglutide and tirzepatide are not on it either way.
Who the 503B list covers and who it does not
The 503B bulks list is for outsourcing facilities. These compounders register with FDA, must meet federal manufacturing standards and may make drugs without a prescription for a named patient.
State-licensed pharmacies that compound under section 503A work under other conditions. FDA set them out on April 1, 2026: each drug is made for one patient against a prescription, and the pharmacy may not regularly compound copies of a drug that is sold commercially. The proposal is about the 503B list only.
The same FDA statement says semaglutide and tirzepatide are on neither the 503B bulks list nor FDA's drug shortage list. Under FDA's reading, outsourcing facilities may not compound them from bulk today, and the proposal would keep it that way.
What this means if you buy compounded now
Nothing in the proposal is final, and FDA says it will weigh the comments before it decides. FDA's own advice to patients is below.
- Compounded semaglutide and compounded tirzepatide are not FDA approved. FDA does not review them for safety, effectiveness or quality before they are sold.
- Get a prescription from your doctor and fill it at a state-licensed pharmacy.
- Be wary of a seller that says its compounded drug is the same as an FDA-approved one.
- Throw out a multi-dose vial 28 days after the first dose, even if some is left.
What happens next
FDA can finalize the proposal as written or change it. Either way it says it will publish a final determination in the Federal Register. This page will carry that date and document number.
More on compounded GLP-1
Sources
Evidence checked November 16, 2026
Every figure above is taken from the document beside it, the FDA label or the trial that produced it, so you can read the source instead of trusting us. How we check sources.
7 documents
- FDA's announcement of the proposal, April 30, 2026FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (FDA)
- The proposal, published May 1, 2026, docket FDA-2018-N-3240Federal Register document 2026-08552
- The comment deadline moved to July 30, 2026Federal Register document 2026-12937
- Every Federal Register document on docket FDA-2018-N-3240Docket FDA-2018-N-3240 (Federal Register)
- FDA's final 503B decisions, none on semaglutide or tirzepatide503B Bulk Drug Substances List (FDA)
- The conditions for 503A pharmacies and 503B outsourcing facilitiesFDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (FDA)
- FDA does not approve compounded drugs or review them before they are sold, and its advice to patientsFDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (FDA)
Prices from the programs' own pages, checked November 16. How we check prices.